How do you pick a goal weight on tirzepatide or semaglutide?
No adult label we checked for tirzepatide (Mounjaro, Zepbound) or semaglutide (Ozempic, Wegovy) sets a goal weight. Australia's obesity algorithm calls for personalised targets, and the UK's NICE guideline assesses risk using BMI and waist. In US label trials, average loss was 20.9% on tirzepatide 15 mg and 14.9% on semaglutide 2.4 mg, and much of it returned after stopping.
Does any label say what your goal weight should be?
No US label we searched for Zepbound, Mounjaro, Wegovy or Ozempic sets a goal weight for adults taking these medicines.1234
The EU, UK, Canadian and Australian labels we checked set none for adults either.56789101112
Australia's Obesity Management Algorithm suggests 10% to 15% loss for a BMI of 30 to 40. Above 40, it suggests over 15%. It calls these targets indicative only, to be personalised between clinician and patient.13
The US labels report 20.9% loss on Zepbound 15 mg at 72 weeks, against 3.1% on placebo.1 On Wegovy 2.4 mg it was 14.9% at 68 weeks, against 2.4% on placebo.3 For a 100 kg person, those averages are about 21 kg and 15 kg. Results varied: 90.9% on Zepbound 15 mg and 83.5% on Wegovy 2.4 mg lost at least 5%, so some people lost less.13
The US Zepbound label links acute gallbladder events to weight reduction. Gallbladder inflammation affected 0.7% of people on Zepbound and 0.2% on placebo.1 The US Wegovy label reports gallbladder inflammation in 0.6% of adults on Wegovy and 0.2% on placebo.3 Our side effects guide covers the other risks.
Which measures can help you set a target?
BMI is a practical measure, but the UK's NICE guideline pairs it with waist-to-height ratio for adults with a BMI under 35.14
NICE puts a healthy BMI at 18.5 to 24.9, overweight at 25 to 29.9 and obesity at 30 or more.14 WHO draws its lines at the same 25 and 30.15
NICE uses lower lines for people with a South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background. Overweight starts at 23 and obesity at 27.5, because health risks appear at a lower BMI.14
NICE advises keeping your waist under half your height.14 At 170 cm, that means a waist under 85 cm.
Should age, muscle or health change your target?
Yes, because NICE says to read BMI with caution from age 65 and in adults with high muscle mass.14
NICE points to a possible protective effect of a slightly higher BMI when older.14 Australia's algorithm says there is no clear BMI target over 65 and puts physical function first. It warns that the mortality risk of weight loss, even intentional, rises with age.13
A SURMOUNT-1 substudy analysed scans from 160 people at 72 weeks. Tirzepatide cut body weight by 21.3% and fat by 33.9%. Lean mass (fat-free tissue, including muscle) fell by 10.9%. About 74% of the loss was fat and 26% lean, close to placebo.16
One counselling step in Canada's obesity guideline assessment chapter is to help set whole-person and functional goals in place of weight-based ones.17 A 2026 review urges caution in people with disordered eating, citing case reports of pathological dietary restriction on these medicines.18
What happens after you reach a goal weight?
In withdrawal trials, weight came back after treatment stopped, so a goal weight needs a plan for what happens next.1920
In SURMOUNT-4, people lost 20.9% on tirzepatide over 36 weeks. Over the next 52 weeks, weight rose 14.0% on placebo and fell a further 5.5% on tirzepatide.19
A year after stopping semaglutide 2.4 mg in the STEP 1 extension, people had regained two-thirds of their weight loss.20
SURMOUNT-MAINTAIN, funded by Lilly, tested lowering the dose after weight loss. Total loss at 112 weeks was 21.9% on the highest tolerated dose, 16.6% on a reduced 5 mg and 9.9% on placebo.21
What do people on GLP-1 medicines report about choosing a goal weight?
From public patient forums: 407 Reddit threads in r/Zepbound, r/mounjarouk, r/Mounjaro, r/Semaglutide, r/WegovyWeightLoss and r/GLPGrad, read from October 2025 to October 2026. Personal reports, not medical evidence.
What people describe
- Not studied Many threads describe using body fat or lean mass, often from a DEXA scan, to set or check a goal. We found no study testing goals set this way.
- Matches NICE Many threads track waist size, most often aiming for a waist under half of height.14
- Partly matches NICE Several threads describe older adults choosing or being advised a higher weight or BMI floor, though the evidence was often disputed. NICE sets no floor, but says to read BMI with caution from age 65 and notes a possible protective effect of a slightly higher BMI.14
- Matches the trials Several threads describe regain or returning hunger after stopping or pausing treatment. The trials measured the weight regain.1920
- Matches a 2026 review Several threads raise disordered-eating concerns. The review records disordered eating on these medicines.18
Advice people share
- Matches a joint advisory Many advise strength training and prioritising protein during weight loss. A joint advisory from four US societies backs resistance training and appropriate diet to preserve muscle and bone.22
- Not studied Several suggest stopping slightly below a goal as a buffer, while others warn against overshooting. We found no trial testing this.
- Label says otherwise Several mention stretching injections past the schedule or splitting doses. The US Zepbound label sets once-weekly maintenance doses of 5, 10 or 15 mg.1
- Label says otherwise A few pursue very low or underweight targets. The US Zepbound label is for excess body weight, and NICE's healthy BMI range starts at 18.5.114
In your country
No adult label we opened sets a goal weight, while the UK and Australian labels add notes, and three countries rely on other labels here.
Australia
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill treated as not approved). Semaglutide tablets, diabetes: Rybelsus approved; whether supplied not confirmed.
Label: For adolescents only, the Australian Wegovy Product Information advises regular review of treatment goals, particularly once a target weight (such as BMI under the 85th percentile) is reached.12
Emergency number: 000
Canada
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen, Zepbound. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Semaglutide Injection (Dr. Reddy’s; shortage reported Jul 2026, lots recalled Aug 2026); Apo-Semaglutide (one lot recalled Aug 2026). Semaglutide tablets, weight: none (no oral Wegovy in Health Canada’s drug database). Semaglutide tablets, diabetes: Rybelsus. Semaglutide approved but not marketed: Sevmia, Poviztra, Plosbrio, Aspen-Semaglutide, Semaglutide Injection (Aspen), Sandoz Semaglutide.
Label: The answer above applies.
Emergency number: 911
France
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: none (Wegovy pill not sold in France). Semaglutide tablets, diabetes: none found (Rybelsus not in France’s medicines database).
Label: The answer above applies.
Emergency number: 15 or 112
Germany
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy Tablette. Semaglutide tablets, diabetes: Rybelsus.
Label: The answer above applies.
Emergency number: 112
India
Sold as: Tirzepatide: Mounjaro, Yurpeak. Semaglutide injection, weight: Wegovy; Poviztra; Noveltreat. Semaglutide injection, diabetes: Ozempic; Obeda (Dr Reddy’s; recalled Jul 2026 over an active-ingredient impurity; on 23 Oct 2026 the company said it planned to relaunch in Nov; resumption not confirmed at 8 Nov 2026; distributors told Reuters it may be discontinued); Sematrinity; GLIPIQ; Semalix (batches recalled Jul 2026); Semanat; Semafull. Semaglutide injection, diabetes and weight: Semaglyn; Mashema; Alterme; Semasize; Obesema; Hepaglide. Semaglutide, diabetes and weight (form not confirmed): Obeda Pro; Obeda Plus (Dr Reddy’s, made by Hetero Labs; in the market from late Jul 2026). Semaglutide injection, use not confirmed: Semanext; Livarise; Sundae. Semaglutide, form and use not confirmed: Samakind; Usema (batches recalled). Semaglutide tablets, weight: not confirmed. Semaglutide tablets, diabetes: Rybelsus; Sembolic; Obeda (tablets not part of the Jul 2026 recall).
Label: We could not open an Indian label for this page, so this answer relies on the US labels and EU product summaries.1356
Emergency number: 112
Saudi Arabia
Sold as: Tirzepatide: Mounjaro, Mounjaro KwikPen. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic; Tasylev; Lugyda; Glucentra. Semaglutide tablets, weight: none (Wegovy pill not registered). Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a Saudi label for this page, so this answer relies on the US labels and EU product summaries.1356
Emergency number: 997 or 911
United Arab Emirates
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Rybelsus.
Label: We could not open a UAE label for this page, so this answer relies on the US labels and EU product summaries.1356
Emergency number: 998 for an ambulance, or 999
United Kingdom
Sold as: Tirzepatide: Mounjaro. Semaglutide injection, weight: Wegovy, including 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy tablets (authorised 11 Jun 2026; retail sale not confirmed). Semaglutide tablets, diabetes: Rybelsus.
Label: The UK SmPCs add a 5% check for weight management. On Mounjaro, it comes 6 months after reaching the highest tolerated dose. On Wegovy, it comes after 6 months of treatment. Anyone who has not lost at least 5% of their starting weight by then needs a decision on continuing.78 The UK Wegovy SmPC also calls for a decision if someone treated for MASH (a fatty liver disease) becomes underweight, at a BMI under 18.5.8
Emergency number: 999
United States
Sold as: Tirzepatide: Zepbound, Mounjaro. Semaglutide injection, weight: Wegovy, including Wegovy HD 7.2 mg. Semaglutide injection, diabetes: Ozempic. Semaglutide tablets, weight: Wegovy pill. Semaglutide tablets, diabetes: Ozempic tablets; Rybelsus (being discontinued).
Label: The answer above applies.
Emergency number: 911
Contact your prescriber or a doctor right away if you have severe stomach pain that may spread to your back, or signs of gallbladder problems such as upper stomach pain or fever.1 See a doctor as soon as you can if you think you may have an eating disorder.24
Read the full picture
Related questions
Sources
- US Zepbound (tirzepatide) prescribing information, Eli Lilly. uspl.lilly.com
- US Mounjaro (tirzepatide) prescribing information, Eli Lilly. uspl.lilly.com
- US Wegovy (semaglutide) prescribing information, Novo Nordisk, on DailyMed. dailymed.nlm.nih.gov
- US Ozempic (semaglutide) prescribing information, Novo Nordisk. novo-pi.com
- EU Mounjaro product information (SmPC), European Medicines Agency. ema.europa.eu
- EU Wegovy product information (SmPC), European Medicines Agency. ema.europa.eu
- UK Mounjaro KwikPen SmPC, electronic Medicines Compendium. medicines.org.uk
- UK Wegovy 2.4 mg FlexTouch SmPC, electronic Medicines Compendium. medicines.org.uk
- Canadian Zepbound (tirzepatide) Product Monograph. pdf.hres.ca
- Canadian Wegovy (semaglutide) Product Monograph. pdf.hres.ca
- Australian Mounjaro Product Information. medsinfo.com.au
- Australian Wegovy Product Information. medsinfo.com.au
- Australian Obesity Management Algorithm, July 2024. diabetessociety.com.au
- NICE guideline NG246, Overweight and obesity management: identifying and assessing overweight, obesity and central adiposity. nice.org.uk
- World Health Organization. Obesity and overweight fact sheet. who.int
- Look M, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. 2025. pmc.ncbi.nlm.nih.gov
- Obesity Canada. Canadian Adult Obesity Clinical Practice Guidelines: assessment chapter. obesitycanada.ca
- Leziak A, et al. The dual role of GLP-1 receptor agonists in weight management and eating disorders. 2026. doi.org
- Aronne LJ, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024. doi.org
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. 2022. pubmed.ncbi.nlm.nih.gov
- Horn DB, et al. Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN). Lancet, 2026. doi.org
- Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory. 2025. pmc.ncbi.nlm.nih.gov
- American College of Emergency Physicians. Know When to Go to the ER. emergencyphysicians.org
- NHS. Eating disorders: overview. nhs.uk
Last checked Nov 9, 2026 · Next review due Nov 9, 2027 · Report an error
How this answer was made. Written by the GLP Guidebook team from the sources above, all checked on Nov 9, 2026. The “What people report” section summarises public patient forum posts we read; it is not medical evidence, and we never pass on advice that goes against the label. It’s general information, not medical advice. Talk to a doctor, pharmacist or other licensed prescriber before starting, stopping or changing any medicine. In an emergency, call your local emergency number. How we write